Have you seen the new evidence supporting antibody-drug conjugates (ADCs) for the treatment of triple-negative breast cancer (TNBC)? Can you recognize treatment directions based on biomarkers, such as HER2-low and HER2 overexpression?
This educational series examines the rapidly evolving landscape of breast cancer treatment. Tune in to hear our globally renowned experts break down current and emerging ADCs that could benefit your patients with TNBC and HER2 breast cancer.
Provided by:
In Partnership with:
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
